智通财经APP获悉，在诺和诺德(NVO.US)终止与远程医疗公司Hims & Hers Health合作后，摩根士丹利发布研报给予Hims & Hers Health(HIMS.US)“与大盘持平”评级，最新目标价40美元。
诺和诺德声明指出，尽管Wegovy药物短缺问题已缓解，但Hims & Hers去年推出的低价复合版本仍未符合联邦相关法规。
诉讼担忧再次浮现，投资者质疑其减肥业务的长期发展轨迹(约占 2025 年预期收入的 30%)。如果诺和诺德对 Hims & Hers 提起诉讼，一个关键问题是 Hims 是否能够在诉讼期间继续提供混合治疗。作为参考，礼来诉讼案的六名被告中有五名继续提供混合 GLP-1 药物。
大摩对 Hims & Hers 平台的咨询过程表明，它引导大多数用户选择其个性化司美格鲁肽选项，而不是品牌选项，前提是用户报告任何副作用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.